Derivatives (4- (benzo (b) thiophen-2-yl) -pyrimidin-2-yl) -amine as inhibitors of IKK-beta for the treatment of cancer and inflammatory diseases.

A compound of formula I: ** ** see formula wherein: R 1 is hydrogen, hydroxy, halo, methylthio, aminosulfonyl, pyrid-2-ylamino, 3-metilaminocarbonilfenilo, -C (O) NR 8 R 9, - ( CH 2) 12 -CH 0-1NHSO 2R 2NHCONHR 13, NHC (O) R 14 or pyrrolidinonyl optionally substituted by ethoxycarbonyl; R 2 is hydrogen, hydroxy, halo, cyano, (C1-C4) or (C1-C4); R 3 is hydrogen, halo or methyl; R 4 is (a) -NR 6 R 7 or (b) aminometilciclohexilo, piperidinyl, 2,2,6,6-tetramethylpiperidin-4-yl, 2,2,6,6-tetramethylpiperidin-4-iletenilo, 4- ( C1-C4) alquilpiperidin-4-yl or pyrrolidinyl; wherein (b) can be optionally substituted with a substituent selected from the group consisting of (C2-C4), cycloalkyl (C3-C6), C (O) R 10 and (C1-C4) alkyl optionally substituted with halo, (C1-C4) -alkyl or (C3-C6); R 5 is hydrogen when n is 1-7 or hydroxy when n is 2-7; R 6 is hydrogen or (C1-C4); R 7 is selected from the group consisting of hydrogen, alkyl yl piperidin-4-(C 1-C 4), optionally substituted with (C 1-C 4), piperidinylcarbonyl optionally substituted by (C 1-C 4), pyrrolidine -3-yl optionally substituted by alkyl (C1-C4) and pyrrolidinylcarbonyl optionally substituted with (C1-C4); alternatively, R 6 and R 7, together with the nitrogen to which they are attached form a ring selected from the group consisting of piperazinyl yl 3-dimethylaminopyrrolidin-1-, homopiperazinyl, 4-Dimethylamino-1-yl, or hexahydro-pyrrolo [3, 4-c] pyrrolyl; wherein the ring may be optionally substituted group consisting of alkenyl (C2-C4) alkyl, (C 3 -C 6), C (O) R 10, and one to three alkyl substituents (C 1-C 4) optionally substituted with hydroxy; R 8 is hydrogen or (C1-C4); R 9 is hydrogen, (C1-C4) alkoxy (C1-C4) alkyl, (C3-C6), thiazolyl, imidazolyl, pyridyl, phenyl optionally substituted with halo, 2-hydroxy-2-phenyl-ethyl, imidazolylethyl, 6 -cloropiridil-3-methyl or furan-2-yl-alkyl (C 1-C 4); alternatively, R8 'and R9 together with the nitrogen to which they are attached form a heterocycle selected from the group consisting of morpholinyl and thiazinyl; R 10 is hydrogen or (C1-C4) or NHR 11; R 11 is hydrogen or (C1-C4); 78 null ES 2329085 T3 R 12 is alkyl (C1-C4), trifluoroalkyl (C1-C4), benzyl or (C3-C6); R 13 is alkyl (C1-C4) alkyl, (C3-C6) or benzyl optionally sustituid (C1-C4), halo, or alkoxy (C1-C 4); R 14 is (C3-C6), piperidinyl, indolylmethyl, or benzyl optionally substituted with 3-dimethylamino-2hidroxipropoxi; with the proviso that when R 4 is piperidinyl, R 1 is -C (O) NR 8 R 9; n is 1-7, with the proviso that n is 1 only when R4 is aminometilciclohexilo or 2,2,6,6-tetramethylpiperidin-4-iletenilo; or its pharmaceutically acceptable salt.